Gilead Sciences, Inc. GILD shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily.
Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89 billion for the quarter, above the Wall Street consensus of $4.45 billion.
Gilead said its projects total product sales between $30 billion and $31 billion this year, equal to what analysts were expecting, Reuters reports.
Separately, social media chatter is circulating that said Gilead Harvoni U.S. sales ($1.707 billion) missed expectations by over 20 percent, while international sales ($1.638 billion) beat by 80 percent.
These figures have not been verified by an analyst; Gilead has not yet returned a request for comment on this issue.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.